These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana. Nii-Trebi NI; Ibe S; Barnor JS; Ishikawa K; Brandful JA; Ofori SB; Yamaoka S; Ampofo WK; Sugiura W PLoS One; 2013; 8(8):e71972. PubMed ID: 23977189 [TBL] [Abstract][Full Text] [Related]
5. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. Santoro MM; Sabin C; Forbici F; Bansi L; Dunn D; Fearnhill E; Boumis E; Nicastri E; Antinori A; Palamara G; Callegaro A; Francisci D; Zoncada A; Maggiolo F; Zazzi M; Perno CF; Ceccherini-Silberstein F; Mussini C HIV Med; 2013 Oct; 14(9):571-7. PubMed ID: 23668660 [TBL] [Abstract][Full Text] [Related]
6. HIV-1 drug resistance and associated factors among adults failing first-line highly active antiretroviral therapy in Ho Chi Minh City, Vietnam. Pham QD; Huynh TK; Luong TT; Tran T; Vu TX; Truong LX HIV Clin Trials; 2013; 14(1):34-44. PubMed ID: 23372113 [TBL] [Abstract][Full Text] [Related]
8. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy. Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463 [TBL] [Abstract][Full Text] [Related]
9. Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey. Musengimana G; Tuyishime E; Kiromera A; Malamba SS; Mulindabigwi A; Habimana MR; Baribwira C; Ribakare M; Habimana SD; DeVos J; Mwesigwa RCN; Kayirangwa E; Semuhore JM; Rwibasira GN; Suthar AB; Remera E Antivir Ther; 2022 Jun; 27(3):13596535221102690. PubMed ID: 35593031 [TBL] [Abstract][Full Text] [Related]
10. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. TenoRes Study Group Lancet Infect Dis; 2016 May; 16(5):565-575. PubMed ID: 26831472 [TBL] [Abstract][Full Text] [Related]
11. Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. Johannessen A; Naman E; Kivuyo SL; Kasubi MJ; Holberg-Petersen M; Matee MI; Gundersen SG; Bruun JN BMC Infect Dis; 2009 Jul; 9():108. PubMed ID: 19583845 [TBL] [Abstract][Full Text] [Related]
12. Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study. Gregson J; Kaleebu P; Marconi VC; van Vuuren C; Ndembi N; Hamers RL; Kanki P; Hoffmann CJ; Lockman S; Pillay D; de Oliveira T; Clumeck N; Hunt G; Kerschberger B; Shafer RW; Yang C; Raizes E; Kantor R; Gupta RK Lancet Infect Dis; 2017 Mar; 17(3):296-304. PubMed ID: 27914856 [TBL] [Abstract][Full Text] [Related]
13. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique. De Luca A; Sidumo ZJ; Zanelli G; Magid NA; Luhanga R; Brambilla D; Liotta G; Mancinelli S; Marazzi MC; Palombi L; Ceffa S BMC Infect Dis; 2017 Sep; 17(1):605. PubMed ID: 28870148 [TBL] [Abstract][Full Text] [Related]
14. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457 [TBL] [Abstract][Full Text] [Related]
15. Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy. Luo XL; Mo LD; Su GS; Huang JP; Wu JY; Su HZ; Huang WH; Luo SD; Ni ZY J Pharmacol Sci; 2019 Apr; 139(4):275-279. PubMed ID: 30928089 [TBL] [Abstract][Full Text] [Related]
16. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA; Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460 [TBL] [Abstract][Full Text] [Related]
17. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine. Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243 [TBL] [Abstract][Full Text] [Related]
18. Cardiometabolic risk factors among HIV patients on antiretroviral therapy. Kiage JN; Heimburger DC; Nyirenda CK; Wellons MF; Bagchi S; Chi BH; Koethe JR; Arnett DK; Kabagambe EK Lipids Health Dis; 2013 Apr; 12():50. PubMed ID: 23575345 [TBL] [Abstract][Full Text] [Related]
19. Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data. Price H; Asboe D; Pozniak A; Gazzard B; Fearnhill E; Pillay D; Dunn D; ; Antivir Ther; 2010; 15(2):203-11. PubMed ID: 20386075 [TBL] [Abstract][Full Text] [Related]
20. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa. van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]